Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a world-class inflammatory bowel disease (IBD) portfolio.
Transforming the Treatment of Inflammatory Bowel Disease
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Latest News from Aeglea
Latest News from Aeglea
Get In Touch With Us
